Dupilumab treatment induces clinical remission in patients with uncontrolled, moderate-to-severe, type 2 inflammatory asthma

被引：0
|
作者：
Pavord, I. [1 ]
Pandit-Abid, N. [2 ]
Israel, E. [3 ,4 ]
Szefler, S. [5 ]
Brusselle, G. [6 ]
Rabe, K. [7 ,8 ]
Chen, Z. [9 ]
Altincatal, A. [10 ]
Amin, N. [9 ]
Khan, A. [11 ]
Lederer, D. H. [9 ]
Zhang, Y. [9 ]
Rowe, P. J. [2 ]
Deniz, Y. [9 ]
Amr, R. [9 ]
Jacob-Nara, J. A. [2 ]
Busse, W. W. [12 ]
机构：
[1] Univ Oxford, Oxford, England
[2] Sanofi, Bridgewater, MA USA
[3] Harvard Med Sch, Boston, MA USA
[4] Brigham & Womens Hosp, Boston, MA USA
[5] Univ Colorado, Sch Med, Aurora, CO USA
[6] Ghent Univ Hosp, Ghent, Belgium
[7] LungenClin Grosshansdorf, Grosshansdorf, Germany
[8] Univ Kiel, Kiel, Germany
[9] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[10] Sanofi, Cambridge, MA USA
[11] Sanofi, Chilly Mazarin, France
[12] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
来源：
ALLERGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
000327
引用
收藏
页码：206 / 207
页数：2
相关论文
共 50 条
  • [11] Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma with fungal sensitization
    Corren, Jonathan
    Hanania, Nicola A.
    Busse, William W.
    Sher, Lawrence D.
    Altincatal, Arman
    Hardin, Megan
    Mannent, Leda P.
    Amin, Nikhil
    Lederer, David J.
    Soler, Xavier
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (10): : 1020 - 1030
  • [12] DUPILUMAB REDUCES BIOMARKERS OF TYPE 2 INFLAMMATION IN CHILDREN WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA
    Bacharier, L.
    Maspero, J.
    Katelaris, C.
    Fiocchi, A.
    Liu, D.
    Lederer, D.
    Hardin, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S33 - S33
  • [13] Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
    Castro, Mario
    Rabe, Klaus F.
    Corren, Jonathan
    Pavord, Ian D.
    Katelaris, Constance H.
    Tohda, Yuji
    Zhang, Bingzhi
    Rice, Megan S.
    Maroni, Jaman
    Rowe, Paul
    Pirozzi, Gianluca
    Amin, Nikhil
    Ruddy, Marcella
    Akinlade, Bolanle
    Graham, Neil M. H.
    Teper, Ariel
    ERJ OPEN RESEARCH, 2020, 6 (01)
  • [14] Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma
    Castro, M.
    Rabe, K. F.
    Kraft, M.
    Corren, J.
    Pavord, I. D.
    Katelaris, C.
    Tohda, Y.
    Rice, M. S.
    Lu, Y.
    Rowe, P.
    Staudinger, H. W.
    Amin, N.
    Akinlade, B.
    Graham, N. M. H.
    Teper, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [15] Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
    Corren, Jonathan
    Jackson, David J.
    Casale, Thomas B.
    Borish, Larry
    Rabe, Klaus F.
    Busse, William W.
    Maspero, Jorge F.
    Jackson, Daniel J.
    Daizadeh, Nadia
    Altincatal, Arman
    Radwan, Amr
    Khodzhayev, Angela
    Djandji, Michel
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    JOURNAL OF ASTHMA AND ALLERGY, 2023, 16 : 249 - 260
  • [16] Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
    Corren, Jonathan
    Katelaris, Constance H.
    Castro, Mario
    Maspero, Jorge F.
    Ford, Linda B.
    Halpin, David M. G.
    Rice, Megan S.
    Radwan, Amr
    Deniz, Yamo
    Rowe, Paul J.
    Teper, Ariel
    Djandji, Michel
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58 (04)
  • [17] Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma with Elevated Type 2 Biomarkers and Fixed Airflow Obstruction
    Hanania, N. A.
    Castro, M.
    Bateman, E. D.
    Pavord, I. D.
    Papi, A.
    FitzGerald, J. M.
    Maspero, J. F.
    Katelaris, C.
    Singh, D.
    Daizadeh, N.
    Pandit-Abid, N.
    Ortiz, B.
    Laws, E.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y.
    Lederer, D. J.
    Hardin, M.
    Siddiqui, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [18] Dupilumab Provides Rapid and Sustained Exacerbation Protection in Patients with Uncontrolled, Moderate-to-Severe Type 2 Inflammatory Asthma Enrolled in the LIBERTY ASTHMA QUEST Study
    Corren, J.
    Rogers, L.
    Papi, A.
    Chen, Z.
    Pandit-Abid, N.
    Rowe, P.
    Deniz, Y.
    Ortiz, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [19] Dupilumab reduces the percentage of patients experiencing severe exacerbations each calendar month throughout the year in patients with type 2 inflammatory, uncontrolled, moderate-to-severe asthma
    Corren, J.
    Domingo, C.
    Daizadeh, N.
    Ortiz, B.
    Djandji, M.
    Rowe, P.
    Crikelair, N.
    Deniz, Y.
    ALLERGY, 2020, 75 : 172 - 172
  • [20] Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype
    Rabe, Klaus F.
    FitzGerald, J. Mark
    Bateman, Eric D.
    Castro, Mario
    Pavord, Ian D.
    Maspero, Jorge F.
    Busse, William W.
    Izuhara, Kenji
    Daizadeh, Nadia
    Ortiz, Benjamin
    Pandit-Abid, Nami
    Rowe, Paul J.
    Deniz, Yamo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (11): : 2916 - +
12345